Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. PIPA544232

Invitrogen™ HMHA1 Polyclonal Antibody
GREENER_CHOICE

Catalog No. PIPA544232
Change view
Click to view available options
Quantity:
100 μL
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIPA544232 100 μL
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. PIPA544232 Supplier Invitrogen™ Supplier No. PA544232
Only null left
Add to Cart
Add to Cart

Description

Rabbit Polyclonal Antibody

Peptide sequence: MMHMQTAPLP VHFQMLCESS KLYDPGQQYA SHVRQLQRDQ EPDVHYDFEP Sequence homology: Cow: 100%; Dog: 100%; Horse: 75%; Human: 100%; Mouse: 100%; Pig: 100%; Rabbit: 75%; Rat: 100%; Zebrafish: 92%.

Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domain which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.
TRUSTED_SUSTAINABILITY

Specifications

Antigen HMHA1
Applications Western Blot
Classification Polyclonal
Concentration 0.5 mg/mL
Conjugate Unconjugated
Formulation PBS with 2% sucrose and 0.09% sodium azide
Gene ARHGAP45
Gene Accession No. Q92619
Gene Alias 6330406L22Rik; ARHGAP45; AW539505; Ha-1; histocompatibility (minor) HA-1; HLA-HA1; Hmha1; KIAA0223; mHag HA-1; Minor histocompatibility antigen HA-1; minor histocompatibility protein HA-1; minor histocompatibility protein HA-1; rho GTPase-activating protein 45; RGD1308662; Rho GTPase activating protein 45; rho GTPase-activating protein 45
Gene Symbols ARHGAP45
Host Species Rabbit
Immunogen Synthetic peptide directed towards the N-terminal of human HMHA1 (aa 512-561).
Purification Method Affinity Chromatography
Quantity 100 μL
Regulatory Status RUO
Primary or Secondary Primary
Gene ID (Entrez) 23526
Target Species Human
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Liquid
Isotype IgG
Show More Show Less

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.